Akebia Therapeutics and U.S. Renal Care announced entry into a multi-year commercial supply contract encompassing all USRC dialysis centers. The contract enables USRC attending physicians to prescribe Vafseo for patients on dialysis as deemed clinically appropriate when it is expected to be available in January 2025. In March 2024, Vafseo was approved by the U.S. Food and Drug Administration for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months. Akebia expects to receive Transitional Drug Add-on Payment Adjustment designation for Vafseo in January 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.